Genesis Health review

Genesis Health shows sermorelin injection at $175 monthly equivalent and NAD⁺ injection at $165, each tied to an annual plan. Those figures are useful headlines but do not establish a monthly debit or a complete annual charge. The pages list shorter options without clear peptide amounts; navigation also calls these first-month prices. A 15-day prebilling cancellation rule now matters when comparing plans. Pharmacy assignment and state eligibility remain unclear.

Genesis Health is a telehealth platform run by Genesis Health International from a published address in Boynton Beach, Florida. It sells compounded semaglutide and tirzepatide injections and brand-name Ozempic, Wegovy and Zepbound on the weight-loss side, with a wellness menu covering sermorelin as an injection and as an orally dissolving tablet, NAD⁺ as an injection, a nasal spray and a face cream, glutathione, methylene blue, MIC+B12, a hair-growth kit and a vardenafil-and-tadalafil product. Plans are described as including a provider consultation, personalized dosing, coaching, community access and free expedited shipping, and its wellness product pages state no membership fees.

An independent licensed provider reviews the online intake and, if appropriate, a 503A pharmacy partner fills the prescription. Genesis Health International Inc is named in terms, but no individual dispensing pharmacy or state-by-state list is given. Consultations, follow-ups and expedited shipping are advertised; required lab charges remain unstated. The refund policy allows initial medical-disqualification and billing-error refunds, with exceptions, but makes orders noncancelable after clinical review or fulfillment begins. Future subscriptions must be canceled by care email at least fifteen days before billing. Late pre-shipment requests may receive a discretionary ten-percent credit for a future order; after shipment, none is offered. FSA/HSA statements on products and in the FAQ conflict.

The public peptide headlines, each labeled for an annual plan, are $175 a month for sermorelin injection, $95 for dissolving tablets, $165 for NAD⁺ injection, $119 for nasal NAD⁺, $110 for glutathione and $155 for NAD⁺ face cream. First-order discounts appear on several products. Monthly, quarterly and six-month labels do not provide a reliable shorter-plan peptide amount, and the initial annual debit and supply are not established. Current fine print refers to the selected plan and actual prescribed product, rather than the older two-month GLP-1 footnote. The separate GLP-1 table lists semaglutide $175 monthly to $1,100 annually and tirzepatide $225 monthly to $1,500 annually, while an FAQ quotes a $296 GLP-1 start; confirm the selected product and charge.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Genesis prints this plainly — its own pages state that compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness or quality, and that its partner pharmacies are US-licensed 503A compounding facilities — but it does not name those pharmacies, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence the wellness line splits three ways and the site does not draw the distinction. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism, but no controlled human trial demonstrates the energy, recovery or body-composition results it is marketed on, and its own product copy hedges with "may support" language for exactly that reason; the dissolving tablet has no comparative bioavailability data published on the site. Injected and intranasal NAD⁺ have no controlled human outcome trials; the oral precursors NR and NMN are the studied forms and they raise blood NAD⁺, a biomarker rather than a demonstrated outcome. The NAD⁺ face cream is further out still — there is no human outcome evidence for topical NAD⁺. If glutathione is supplied by injection, that route has essentially no controlled human outcome data either. Individual results vary.